Abbott Laboratories Corporation

George M Carrera, Jr

George S Sheppard

James B Summers, Jr

Steven K Davidsen

Douglas H Steinman

H Robin Heyman

James H Holms

Daisy Pireh

David S Garvey

Yun He

Nan-Horng Lin

Stephen W Fesik

Alan S Florjancic

Robert B Garland

Michael L Curtin

Paul D May

Suzanne A Lebold

Michael B Martin

Youe-Kong Shue

Edmund L Lee

Lianhong Xu

Stephen P Arneric

James G Phillips

Denise E Guinn

Compounds of formula ##STR1## or a pharmaceutically acceptable salt thereof inhibit matrix metalloproteinases and TNF.alpha. secretion and are useful in the treatment of inflammatory disease states. Also disclosed are matrix metalloproteinases and TNF.alpha. secretion inhibiting compositions and a method for inhibiting matrix metalloproteinases and TNF.alpha. secretion.

Biphenyl hydroxamate inhibitors of matrix metalloproteinases

The present invention provides compounds of formula ##STR1## wherein Y is &gt;C.dbd.O or &gt;S(O).sub.t wherein t is 1 or 2 and the pharmaceutically acceptable salts thereof which are potent antagonists of PAF and are useful in the treatment of PAF-related disorders including asthma, rhinitis, shock, respiratory distress syndrome, acute inflammation, transplanted organ rejection, gastrointestinal ulceration, allergic skin diseases, delayed cellular immunity, parturition, fetal lung maturation, and cellular differentiation.

Indole piperazine platelet activating factor antagonists

The present invention provides compounds of formula ##STR1## and the pharmaceutically acceptable salts thereof which are potent antagonists of PAF and are useful in the treatment of PAF-related disorders including asthma, shock, respiratory distress syndrome, acute inflammation, transplanted organ rejection, gastrointestinal ulceration, allergic skin diseases, delayed cellular immunity, parturition, fetal lung maturation, and cellular differentiation.

Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet

The present invention relates to compounds of formula ##STR1## and the pharmaceutically acceptable salts thereof which are potent antagonists of PAF and are useful in the treatment of PAF-related disorders including asthma, shock, respiratory distress syndrome, acute inflammation, transplanted organ rejection, gastrointestinal ulceration, allergic skin diseases, delayed cellular immunity, parturition, fetal lung maturation, and cellular differentiation.

Platelet activating factor antagonists: imidazopyridine indoles

Platelet activating factor antagonists

Novel isoxazole isothiazole and pyrazole compounds of the formula: ##STR1## wherein A, R.sup.1, and R.sup.2 are specifically defined, or pharmaceutical salts thereof, are selective and potent cholinergic ligands at neuronal nicotinic receptors, useful in the treatment of cognitive, neurological and mental disorders characterized by decreased cholinergic function, as well as in the treatment of alcohol intoxication and petit real absence epilepsy.

Isoxazole, isothiazole and pyrazole compounds that enhance cognitive

Growing community of inventors

Des Plaines, IL, United States of America

George M Carrera, Jr